Article
Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study.
Expert review of gastroenterology & hepatology - 1 Dec 2019
Said Mohamed, Soliman Zeinab, Daebes Hosam, M El-Nahaas Saeed, El-Serafy Magdy
Abstract excerpt
Background: Non-invasive prediction of significant liver fibrosis and gastro-esophageal varices during mass treatment for HCV is crucial.The aim is to validate the accuracy of FIB-4 & APRI for predicting significant fibrosis in chronic HCV patients during mass treatment with directly acting anti-viral agents (DAAs) & their validity for predicting varices.Methods: We did a search in a database of 21,617 patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
